The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
A 60-year-old woman died after being trapped naked in an airing cupboard at a holiday complex near Machynlleth.
Patchy drizzle will continue tonight, with coastal low cloud soon moving back inland.
Barclays has announced 203 job losses at its Merchant Services Operations and Technology Divisions in Pentwyn.